Zai Lab Limited American Depositary Shares (ZLAB) Stock
Key stats
- Market cap
- $2.93B
- Price / Earnings ratio
- -13.3x
- EPS (TTM)
- -$1.90
- Volume
- Loading
- 52-week high
- $29.02
- 52-week low
- $15.96
Source: third-party data provider, as of November 18, 2026
Compare with ZLAB
Recent news

Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
ZLAB

Zai Lab Announces Participation in Investor Conferences in November 2026
Zai Lab Announces Participation in Investor Conferences in November 2026
ZLAB

Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
ZLAB

Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?
Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?
ZLAB
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 46.30
- MACD 12/26/9
- 0.13
- EMA 9 of MACD
- 0.07
- MACD histogram
- 0.06
- SMA 50
- $24.52
- Price below SMA 50
- EMA 50
- $24.14
- Price below EMA 50
- SMA 200
- $21.37
- Price above SMA 200
- EMA 200
- $21.68
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 17, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.20 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
ZLAB

Zai Lab Announces Participation in Investor Conferences in November 2026
Zai Lab Announces Participation in Investor Conferences in November 2026
ZLAB

Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
ZLAB

Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?
Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?
ZLAB

Zai Lab Q3 Earnings Call Highlights
Zai Lab Q3 Earnings Call Highlights
ZLAB

Zai Lab Limited (ZLAB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Zai Lab Limited (ZLAB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
ZLAB

Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas
Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas
ZLAB

Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer Study
Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer Study
ZLAB

Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
ZLAB

Zai Lab Announces $250 Million Private Placement
Zai Lab Announces $250 Million Private Placement
ZLAB
News tone: automated (AI) classification of the article's content, not a price prediction.
About Zai Lab Limited American Depositary Shares
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Ying Du Ph.D. | Founder, Chairperson & CEO | 1966 |
| Dr. Yajing Chen Ph.D. | Chief Financial Officer | 1968 |
| Dr. James Yan DABT, M.D., Ph.D. | Chief Operating Officer of Global R&D | 1964 |
| Dr. Rafael G. Amado M.D. | President and Head of Global Research & Development | 1964 |
| Mr. Frazor Titus Edmondson III, J.D. | Chief Legal Officer & Corporate Secretary | 1966 |
| Ms. Christine Chiou | Senior VP & Head of Investor Relations | — |
| Shaun Maccoun | Executive Director of Global Communications | — |
| Dr. Shan He Ph.D. | Senior VP & Chief Business Officer | — |
| Xiaoyu Chen | Executive Director of Regional Communications | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 18, 2026
Technical indicators
- RSI 14
- 46.30
- MACD 12/26/9
- 0.13
- EMA 9 of MACD
- 0.07
- MACD histogram
- 0.06
- SMA 50
- $24.52
- Price below SMA 50
- EMA 50
- $24.14
- Price below EMA 50
- SMA 200
- $21.37
- Price above SMA 200
- EMA 200
- $21.68
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 17, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -17.7 | -11.8 | ||||||||||
| 2022 | -22.9 | +2.1 | -16.3 | -12.1 | -26.4 | +17.6 | +5.2 | +18.9 | -26.1 | -35.0 | +54.1 | -15.1 |
| 2023 | +36.6 | -12.6 | -17.6 | +3.0 | -6.6 | -16.0 | +4.5 | -13.2 | -6.9 | +5.7 | +10.3 | -0.6 |
| 2024 | -17.2 | -6.8 | -24.1 | -5.5 | +11.8 | -3.7 | +10.1 | +8.1 | +24.8 | +21.6 | -5.3 | -10.3 |
| 2025 | +9.6 | +26.5 | +13.9 | -15.0 | -3.2 | +12.1 | +7.5 | -10.1 | +1.6 | -24.1 | -23.7 | -11.3 |
| 2026 | -4.2 | +17.9 | +2.1 | +6.4 | -17.9 | +11.2 | -4.6 | +40.0 | +4.1 | -13.5 | +8.6 |



